TLDR: Medable has launched Agent Studio, the first agentic AI platform specifically designed for life sciences, alongside CRA Agent for clinical trial monitoring. This innovation aims to eliminate inefficiencies, accelerate drug development, and reduce costs by automating complex workflows and freeing up human potential in clinical research.
Palo Alto, CA – September 4, 2025 – Medable, a leading technology provider for clinical development, today announced the launch of Agent Studio, heralded as the industry’s first agentic AI platform purpose-built for the life sciences sector. This significant advancement is accompanied by the introduction of CRA Agent, an out-of-the-box solution designed to enhance clinical trial monitoring.
The new platform is set to address long-standing operational inefficiencies that have historically plagued clinical development, often resulting in new drugs spending approximately 45% of their development time in ‘white space’ – unproductive periods between trial phases. Agent Studio is engineered to not only eliminate this white space but also to remove critical bottlenecks that hinder trial processes.
Dr. Michelle Longmire, CEO and co-founder of Medable, emphasized the transformative potential of the new offering. “Agent Studio is more than just technology – it’s a catalyst to unleash greater human potential in life sciences,” she stated. “It frees teams from the bottlenecks of legacy systems, accelerates trials, reduces costs, and ultimately helps bring medicines to patients faster. We believe this is a once-in-a-generation leap forward in how clinical research gets done.”
Agent Studio functions as a no-code agent-builder, empowering clinical teams to rapidly custom-configure AI agents tailored to their specific needs. These purpose-fit agents are designed to streamline complex trial workflows, including critical areas such as protocol development, trial planning, and optimization.
Complementing Agent Studio, the CRA Agent is an immediate-use solution that runs on the new platform. It is specifically designed to automate routine tasks in clinical trial monitoring, thereby allowing clinical research associates to dedicate their expertise to more critical and nuanced aspects of their work.
Tim Smith, Chief Technology Officer and co-founder of Medable, highlighted the industry’s need for such innovation. “The inherent linear processes of clinical research cause delays at nearly every critical point of a trial,” Smith explained. “Agent Studio, designed specifically for the inherent complexities of this industry, will solve longstanding problems and allow the industry to completely re-imagine drug development.”
Medable’s broader impact on clinical research is already well-established. Its AI-powered clinical trials platform is recognized for enhancing speed, scalability, and patient access. The platform has been deployed in nearly 400 trials across 70 countries and 120 languages, serving over one million patients globally. Medable was also awarded Best Digital Health Solution by the Galien Foundation.
Both Medable Agent Studio and CRA Agent are available immediately. Interested parties can see a live demonstration at the DPharm conference, scheduled for September 16-17, 2025, in Philadelphia at Medable Booth #300.
Also Read:
- DeepL Unveils Autonomous AI Agent, Revolutionizing Business Workflows Beyond Translation
- Google Unleashes ‘Jules’ Autonomous AI Coding Agent, Intensifying AI Development Race
In related news, Medable CEO and Co-Founder Michelle Longmire is also slated to present a corporate update at the Morgan Stanley Global Healthcare Conference in New York City on Tuesday, September 9th, 2025.
